The clinical use of fibrinolytic agents.
Two fibrinolytic drugs, streptokinase and urokinase, have undergone extensive clinical evaluation in the past fifteen years. Current evidence suggests that these agents may become the drugs of choice in the treatment of certain patients with venous thrombosis and pulmonary embolism. The ultimate usefulness of fibrinolytic therapy in the treatment of thrombotic conditions other than venous thrombosis and pulmonary embolism has not yet been determined.
D010450:Endopeptidases / Q000627:therapeutic use*; D006801:Humans; D010690:Phlebography; D011655:Pulmonary Embolism / Q000188:drug therapy*; D013300:Streptokinase / Q000494:pharmacology / Q000627:therapeutic use*; D013924:Thrombophlebitis / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology / Q000627:therapeutic use*
D010450:Endopeptidases; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator